NASDAQ
10.04.26 | 22:00
2,020 US-Dollar
+2,02 % +0,040
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Milestone Pharmaceuticals initiiert Real-World-Studie für PSVT-Medikament CARDAMYST | 8 | Investing.com Deutsch | ||
| Fr | Milestone Pharmaceuticals plans real-world PSVT registry study | 1 | Investing.com | ||
| Fr | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients With PSVT | 1 | GlobeNewswire (USA) | ||
| Do | Raymond James startet Coverage für Milestone Pharmaceuticals mit "Strong Buy" und sieht fast 200 % Kurspotenzial | 8 | Investing.com Deutsch | ||
| Do | Raymond James initiates Milestone Pharmaceuticals stock coverage with Strong Buy | 7 | Investing.com | ||
| 20.03. | Why Milestone Pharma Stock Is Taking A Dive Today | 10 | Benzinga.com | ||
| 20.03. | Milestone Pharmaceuticals GAAP EPS of -$0.75, revenue of $1.55M | 2 | Seeking Alpha | ||
| MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 20.03. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 20.03. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | 512 | GlobeNewswire (Europe) | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| 20.03. | Milestone Pharmaceuticals Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
| 20.03. | Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts | 16 | Benzinga.com | ||
| 16.03. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Present Data on CARDAMYST (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session | 5 | GlobeNewswire (USA) | ||
| 10.02. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer | 565 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance... ► Artikel lesen | |
| 03.02. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 13 | GlobeNewswire (USA) | ||
| 26.01. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 26.01. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia ... | 620 | GlobeNewswire (Europe) | CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay cap for eligible commercially insured... ► Artikel lesen | |
| 13.01. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.01. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.12.25 | Milestone Pharmaceuticals: TD Cowen stuft Aktie nach FDA-Zulassung auf 'Buy' hoch | 18 | Investing.com Deutsch | ||
| 15.12.25 | Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval | 9 | Investing.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,120 | -0,82 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.04.2026... ► Artikel lesen | |
| PFIZER | 22,845 | -0,44 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| GILEAD SCIENCES | 118,00 | -0,46 % | Evotec kassiert Millionen-Exit: Gilead-Deal bringt frisches Kapital - kommt jetzt neuer Schwung? | Evotec meldet einen lukrativen Beteiligungs-Exit - und liefert damit genau das, worauf Investoren gehofft haben. Durch die Übernahme der Biotech-Firma Tubulis durch Gilead Sciences winken Evotec rund... ► Artikel lesen | |
| ELI LILLY | 800,40 | -0,09 % | Deutlich höhere Dosis: Wegovy-Offensive: Novo Nordisk kontert Eli Lilly mit Mega-Dosis | © Foto: Christian Schultz/dpaNovo Nordisk geht in die Offensive: Mit einer deutlich höheren Wegovy-Dosis will der Konzern im boomenden Markt für Abnehmmedikamente verlorene Marktanteile zurückholen... ► Artikel lesen | |
| MERCK & CO | 103,54 | 0,00 % | Merck Launches Tender Offer To Acquire Terns Pharmaceuticals | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) said Tuesday it has commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc. (TERN). The move follows... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 371,65 | -0,13 % | Vertex Licenses Halozyme's Hypercon Technology For Use In Up To Three Drug Targets | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Halozyme Therapeutics (HALO) announced its subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex... ► Artikel lesen | |
| EYEPOINT | 12,100 | 0,00 % | EyePoint, Inc.: EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | - Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 - - Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME -... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 24,450 | +0,82 % | Assembly Biosciences und der 40-Milliarden-Dollar-Markt - Übernahme-Rallye voraus? | Die Aktie von Assembly Biosciences gehört derzeit zu den auffälligsten Diskrepanzen zwischen wissenschaftlichem Potenzial und Börsenbewertung im Biotechnologiesektor. Während das Unternehmen an neuartigen... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 17,900 | -0,33 % | Santhera Pharmaceuticals Holding AG: Full Year 2025 Trading Update | Ad hoc announcement pursuant to Art. 53 LR
AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth
Pratteln, Switzerland, March 12, 2026 - Santhera Pharmaceuticals... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 16,550 | +3,12 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| ACHIEVE LIFE SCIENCES | 2,880 | -2,70 % | Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| ALTIMMUNE | 2,760 | 0,00 % | Altimmune, Inc: Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 171,00 | -1,16 % | Ligand Pharmaceuticals: Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team | JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 165,00 | -0,33 % | Prognose massiv erhöht - Wird der australische Psychodelika-Spezialist Bioxyne zum neuen Branchenliebling? | ||
| SELLAS LIFE SCIENCES | 4,100 | +0,99 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen |
MILESTONE PHARMACEUTICALS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,040 (+2,02 %) liegt der Kurs bei 2,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MILESTONE PHARMACEUTICALS INC finden Sie auf Wallstreet Online.